UPDATE 1-Catalent pushes into gene therapy with $1.2 bln buyout of Paragon Bioservices
April 15, 2019 at 07:38 AM EDT
Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments.